tirzepatide obesity fda Grants a New Indication for Management FDA approval for Zepbound (tirzepatide)

(2014) 221:R6373

It works by activating two hormone pathways: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors

Who May Benefit More from Injections

For approximately 70% of patients, nausea resolves substantially within 46 weeks

From Hospital Tray to Home Delivery: Why the HHS Pledge Points Directly to MTM Programs HHS just launched the Make Hospital Food Healthier Pledge

How Our Program Works: Unlike quick-fix diets, Altitude's medical weight loss addresses weight at a physiological level using GLP-1 medications that naturally: Combined with comprehensive support, clients typically lose 15-20% of body weight over 6-12 months